LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kite Pharma, Inc. (“Kite” or the “Company”) (Nasdaq: KITE).
If you purchased or otherwise acquired Kite shares, and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The investigation focuses on whether Kite and certain of its officers and/or directors violated federal securities laws. On May 8, 2017, the Company disclosed the death of a cancer patient following treatment with Kite’s lead product candidate, KTE-C19, a CAR-based therapy that targets the CD19 antigen. When this news was announced, Kite’s stock price fell.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.